Antengene Corporation Ltd. said South Korea’s National Health Insurance Service approved reimbursement for XPOVIO (selinexor) in combination with bortezomib and dexamethasone for adult multiple myeloma patients after one prior therapy, effective March 1, 2026. The company said this is XPOVIO’s second reimbursed indication in South Korea; XPOVIO has three approved indications in the country across multiple myeloma and diffuse large B-cell lymphoma, with two included in the national reimbursement scheme. Antengene added that XPOVIO has been approved in ten APAC countries and regions and is included in national insurance schemes in five markets: mainland China, Taiwan, Australia, Singapore and South Korea.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603011930PR_NEWS_USPR_____CN97582) on March 02, 2026, and is solely responsible for the information contained therein.